Literature DB >> 7055894

Evaluation of a commercially available radioimmunoassay kit for measurement of doxorubicin in plasma.

E Piall, G W Aherne, V Marks.   

Abstract

We evaluated a commercially available (Diagnostic Biochemistry Inc.) doxorubicin 125I radioimmunoassay kit. This kit gave a high apparent doxorubicin concentration (greater than 12 micrograms/L), which was not linearly related to dilution, for two pools of normal human serum and plasma and also for samples collected from patients before they received the drug. In contrast, a doxorubicin 3H radioimmunoassay developed by us gave a low blank (2 micrograms/L), which was linearly related to dilution, for the same pools and patients' samples. Doxorubicin concentrations in the plasma of patients receiving the drug were compared by the two methods; the kit gave results five- to 10-fold those obtained with our assay. High nonspecific interference by serum and plasma as measured by the 125I radioimmunoassay must therefore be borne in mind by users of the kit, and we suggest that results should be corrected for these nonspecific effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055894

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts.

Authors:  M V Pimm; M A Paul; Y Ogumuyiwa; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

Authors:  H P Henneberry; G W Aherne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.